Website: Cisbio Bioassays

General description
Cisbio Bioassays is a privately held company. It is committed to improving human healthcare with more than 20 years of experience in the fields of medical diagnostic and drug discovery. It develops assays based on its propriety HTRF® and Taglite® technologies and is developing novel drug discovery and diagnostics bioassays. The R&D department consists of ~40 persons and is led by Eric Trinquet.

Key research facilities, infrastructure and equipment
Fully operational organic synthesis, biology, cell-culture and diagnostics labs including HPLC, mass spectrometry, spectrophotometers, ELISA, Fluorescence, RIA readers and fluorescence microscopy. Its facility and processes comply with ISO certification.

Previous and current involvement in research and training programmes
Previously involved in the FP7-ITN project TOPBIO as and in the ITN Oncornet program as Partner. Furthermore, Cisbio has an extensive network of (inter)national scientific partners, which includes funding, and training of PhD students. Most noticeable is our ongoing collaboration with the Institute Génomique Fonctionelle (IGF) in Montpellier. Cisbio is involved in several collaborative programmes supported by national research grants (ANR).

Key persons and expertise

Dr. Eric Trinquet – Vice president R&D, 20 years R&D experience in GPCR and assay technology. He supervises more than 30 scientists including PhD’s. He teaches assay technology- and fluorescence courses at Montpellier and Marseille Universities

Dr. Thomas Roux – Head of the GPCR & Molecular Interactions Team. Expert in GPCR and binding assays.

Dr. Jurriaan Zwier – research scientist/ R&D project manager. Expert in Photophysics.